Scottish Medicines Consortium accepts five new medicines for use, including new diabetes treatment

The Scottish Medicines Consortium (SMC) has accepted 5 new medicines for routine use by NHS Scotland, it has announced. The medicines accepted include: Sorafenib (Nexavar) for liver cancer Tolvaptan (Jinarc) for autosomal dominant polycystic kidney disease (ADPKD) Netupitant/palonosetron (Akynzeo), a combination of two medicines which can be used to prevent and treat nausea brought on by cancer chemotherapy Dulaglutide (Trulicity) for the treatment of type 2 diabetes  Albiglutide (Eperzan), also for the treatment of type 2 diabetes. Sorafenib and tolvaptan were accepted for use after consideration under SMC’s PACE (Patient and Clinician Engagement) process. PACE aims to improve patient access